FCM
DYN icon

Frontier Capital Management’s Dyne Therapeutics DYN Stock Holding History

Frontier Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Buy
874,138
+52,289
+6% +$972K 0.18% 189
2026
Q1 		$14.9M Sell
821,849
-317,019
-28% -$5.47M 0.15% 193
2025
Q4 		$22.3M Buy
1,138,868
+227,949
+25% +$4.32M 0.24% 154
2025
Q3 		$11.5M Buy
910,919
+121,494
+15% +$1.39M 0.1% 235
2025
Q2 		$7.52M Buy
789,425
+499,822
+173% +$5.5M 0.07% 264
2025
Q1 		$3.03M Sell
289,603
-8,449
-3% -$121K 0.03% 272
2024
Q4 		$7.02M Buy
+298,052
New +$8.82M 0.07% 239

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Frontier Capital Management's DYN Position: Q2 2026 in Review

Frontier Capital Management increased its Dyne Therapeutics (DYN) stake by 6.4% in Q2 2026, buying an estimated $972K and bringing the position to 874,138 shares worth $19.4M. The position accounts for 0.18% of the portfolio, ranked #189.

Frontier Capital Management first reported a position in DYN in Q4 2024 and has held it in 7 quarters since. The position peaked at $22.3M in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Frontier Capital Management held 874,138 shares of Dyne Therapeutics worth $19.4M as of Q2 2026.
  • Frontier Capital Management bought 52,289 Dyne Therapeutics shares in Q2 2026, an estimated $972K.
  • Dyne Therapeutics made up 0.18% of Frontier Capital Management's portfolio in Q2 2026, its #189 holding.
  • Frontier Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Frontier Capital Management's Dyne Therapeutics position peaked at $22.3M in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.